VG 1177

Drug Profile

VG 1177

Alternative Names: APi 1177; VG-1177; VGV-X

Latest Information Update: 14 Mar 2015

Price : $50

At a glance

  • Originator Viral Genetics
  • Developer University of Utah; VG Life Sciences
  • Class Antiretrovirals; Peptides
  • Mechanism of Action Immunomodulators; Invariant chain inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain injuries; Epilepsy; HIV infections; Preeclampsia
  • Research Inflammatory bowel diseases

Most Recent Events

  • 02 Mar 2015 VG Life Sciences granted a composition of matter patent in USA
  • 29 Jan 2015 Early research in Inflammatory bowel disease in USA (unspecified route) before January 2015
  • 29 Jan 2015 VG Life Sciences has patent protection for a method of treating inflammatory bowel disease through the administration of a CLIP-inducing agent in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top